Insider Purchases: Inside the Buy
Tag: insider buying
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Will Profits From Marriott Vacations (VAC) Help You Unwind?
Insiders are buying, institutions are lounging, and dividends are flowing. Marriott Vacations Worldwide (VAC) might be your next profitable getaway — with a 3.9% yield and room to grow. But are there risks under the palm trees?
Insiders Are Buying ConocoPhillips. Should You?
Insiders are drilling into COP shares—and they're not alone. With a $10B return plan, strong reserves, and a smart buyout of Marathon Oil, ConocoPhillips might just be the contrarian pick of the year. Here's the fun, smart breakdown.
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
Oscar Health: Its Own Is Shining and Insiders Knew!
Co-founder Joshua Kushner and Thrive Partners bought over $23 million of Oscar Health stock in late 2024. Since then? Record earnings, soaring revenue, and a stock still (surprisingly) within range. A healthy bet — or just a well-insured hunch?
CEO Bought Shares: Is Full House Worth Betting the House?
Full House Resorts is growing fast—but still bleeding cash. The CEO’s massive insider buy may hint at a turnaround, but with debt looming and expansion plans on the table, is FLL worth a gamble? We break it down—odds, icons, and all.
Can Robinhood Still Steal the Show?
Robinhood’s got a new backer — and it’s no amateur. Christopher Payne (ex-DoorDash, Tinder, eBay) just went all in with a bold $2M+ insider buy. Add in huge crypto growth, a string of acquisitions, and global ambitions… and suddenly Robinhood doesn’t just look ready — it looks legendary. Is $HOOD still a buy? Let’s break it down.
Vera Bradley: The Bags Are Pretty; the Financials? Not So Much
The bags? Still adorable. The stock? Still near record lows. With insiders finally buying and a CEO exit underway, is Vera Bradley set for a stylish rebound — or is it still stuck in the clearance bin?
Magnera: Insiders Keep Buying… Should You?
Magnera’s boardroom is buying diapers—literally. With insiders piling in and free cash flow returning, this specialty materials firm might be worth more than just its wipes. But don’t forget the debt and diaper jokes.
Can Lyft Ever Lift Off or Will It Forever Uber-Underwhelm?
CEO David Risher has been scooping up Lyft shares like surge-priced burritos—and with record rides, rising cash flow, and a $750M buyback plan, the bullish case is stronger than ever. But can LYFT finally fly—or is Uber still driving the narrative?